Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow: 2012-2024

Historic Net Cash Flow for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to -$32.7 million.

  • Ultragenyx Pharmaceutical's Net Cash Flow rose 107.78% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year decrease of 35.07%. This contributed to the annual value of -$32.7 million for FY2024, which is 140.22% down from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Net Cash Flow stood at -$32.7 million, which was down 140.22% from $81.3 million recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Cash Flow ranged from a high of $288.9 million in FY2020 and a low of -$415.5 million during FY2021.
  • For the 3-year period, Ultragenyx Pharmaceutical's Net Cash Flow averaged around -$40.8 million, with its median value being -$32.7 million (2024).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Net Cash Flow crashed by 243.81% in 2021, and later spiked by 147.59% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Net Cash Flow (Yearly) stood at $288.9 million in 2020, then plummeted by 243.81% to -$415.5 million in 2021, then spiked by 58.87% to -$170.9 million in 2022, then spiked by 147.59% to $81.3 million in 2023, then plummeted by 140.22% to -$32.7 million in 2024.